Business Wire

CA-INVIVOSCRIBE

8.5.2024 16:01:30 CEST | Business Wire | Press release

Share
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT).

This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software. Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant.

A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population.

Dr. Hourigan, Director of the Virginia Tech FBRI Cancer Research Center in Washington, DC and Principal Investigator of the study, remarked, "This research underscores the value of pre-transplant testing for residual FLT3-ITD in adults with AML. The association of MRD test results with post-transplant outcomes opens up the potential of refining treatment strategies to improve survival."

Moving forward, the study calls for further research to explore alternative approaches for high-risk populations who may not benefit from current standard care protocols.

Dr. Jeff Miller, CEO/CSO at Invivoscribe commented, "We are thrilled to see the remarkable association of clinical outcomes that were so clearly delineated using our research use only test and software. This research study enhances our understanding of AML monitoring and treatment."

About Invivoscribe
Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized research reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. For additional information, please visit www.invivoscribe.com or contact us at inquiry@invivoscribe.com and follow us on Linked In.

1. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia, Dillon et al, JAMA Oncology, Published online May 2, 2024.
2. DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant, Dillon et al, JAMA 2023; 329 (9): 745-755

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508192559/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Launches Quest Builder and Backpack, Enabling Video Game Developers to Reward Players With Items to Collect, Own, and Give Away17.11.2026 15:00:00 CET | Press release

Xsolla Expands Its Core Platform With Xsolla Quest Builder and Backpack to Help Developers and Brands Use Digital Items to Attract and Retain Players Xsolla (USA), Inc., a global commerce company, today announced the launch of Xsolla Quest Builder, a no-code tool that lets video game developers reward players with digital items for reaching goals tracked through game events, alongside Xsolla Backpack, a persistent inventory where players keep those items. Xsolla Quest Builder helps developers acquire new users, improve retention and lifetime value, and learn what players value and want in their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117128292/en/ Graphic: Xsolla Across the industry, players want more value from games and the digital items they acquire to enhance their in-game experience. To address this, along with rising user acquisition costs facing game developers, Xsolla is introducing a new way for pla

Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 15:00:00 CET | Press release

Trulioo customers can now verify identities and assess fraud risk in one integrated platform Trulioo and Bureau today announced a joint go-to-market partnership that adds Bureau’s device and behavioral intelligence, alongside its proprietary cross-business network graph intelligence for identifying connected fraud activity, to Trulioo’s global risk intelligence platform for fraud and financial crimes. Together, the companies are helping banks, fintechs, payments companies and marketplaces in APAC and the U.S. confirm who someone is and assess whether to trust them, all on one platform. AI is making fraud more complex and harder to detect, and organizations need stronger defenses to keep pace. Identity verification is only part of the picture; businesses also need to understand the risk behind every interaction, from onboarding throughout the customer journey. By partnering with Bureau, Trulioo is adding device and behavioral intelligence to its identity verification and risk signals, c

Phison Launches Purpose-Built Storage Solutions for New Space Economy17.11.2026 15:00:00 CET | Press release

New purpose-built Pascari Space storage solutions deliver mission-specific reliability, resilience and customization for spacecraft, lunar and orbital data centers Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of Pascari Space, a new category of purpose-built SSD solutions engineered for commercial outer space applications and orbital infrastructure, on display this week at the SC26 conference. Built upon Phison's decades of NAND engineering expertise and flight-proven storage heritage, Pascari Space leverages Phison IMAGIN+ customization and design services to deliver mission-specific storage solutions built to withstand the extreme demands of outer space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117623865/en/ Phison Launches Purpose-Built Storage Solutions for New Space Economy As terrestrial data infrastructure faces mounti

Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprises17.11.2026 15:00:00 CET | Press release

Turnkey system combines high-performance private AI inference, generative business intelligence and persistent enterprise storage for operational resilience Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of the Phison AI Data Platform (AIDP) with generative business intelligence (GenBI), a turnkey, sovereign AI system that will be showcased at Supercomputing 2026 (SC26) in booth #5413. Powered by Pascari aiDAPTIV ™ Cache Memory technology, Phison AIDP combines locally hosted AI models, integrated inference services, governed analytics and persistent enterprise storage to help organizations unlock business intelligence while maintaining control over their data, infrastructure and AI operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117045294/en/ Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprise

IQM unveils Halocene upgrade program at SC26, creating a path to over 1,000 qubits while accelerating integration with AI-based applications17.11.2026 15:00:00 CET | Press release

IQM Halocene, the company’s error-correction product line, now offers an upgrade path to over 1,000 qubits on the way to fault-tolerant quantum computing Built on IQM’s experience integrating and upgrading more quantum computers in HPC centers than any other company IQM’s HPC integration service, included with each upgrade, connects every new Halocene system to a center’s existing infrastructure, schedulers and GPU platforms, so it is productive from day one Upgrades without downtime, more value from each upgrade and continuity of software, workflows and skills from one system to the next New customers can start now and grow with Halocene, while existing customers can move to each new system seamlessly IQM Quantum Computers (Nasdaq: IQMX), a global leader in integrated quantum computing, today announced an upgrade program for IQM Halocene, its error-correction product line, that gives customers a path from the 150-qubit system of today to the over 1,000-qubit system of the future. Cust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye